AR072943A1 - Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo - Google Patents

Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo

Info

Publication number
AR072943A1
AR072943A1 ARP080103726A ARP080103726A AR072943A1 AR 072943 A1 AR072943 A1 AR 072943A1 AR P080103726 A ARP080103726 A AR P080103726A AR P080103726 A ARP080103726 A AR P080103726A AR 072943 A1 AR072943 A1 AR 072943A1
Authority
AR
Argentina
Prior art keywords
compound
same
pharmaceutical composition
formula
mixture
Prior art date
Application number
ARP080103726A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AR072943A1 publication Critical patent/AR072943A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El compuesto de formula (1) es un agonista selectivo del adrenoreceptor beta2 de accion prolongada, estable en el agua, que se utiliza como broncodilatador en el tratamiento de la broncoconstriccion asociada con una enfermedad obstructiva reversible de las vías respiratorias y similares. Reivindicacion 2: Una mezcla de isomeros de N-[2-hidroxi-5-[1-hidroxi-2-[[(2-(4-hidroxifenil)-1-metiletil]amino]etil]-fenil]acetamida, caracterizado porque la mezcla comprende al menos 90% en peso del isomero. Reivindicacion 3: Un proceso para la preparacion del compuesto de formula (1) caracterizado porque comprende hacer reaccionar un compuesto de formula (2) en la cual P1 representa un átomo de hidrogeno o un grupo protector hidroxilo, con un compuesto de la formula (3) en el cual P2 representa un átomo de hidrogeno o un grupo protector hidroxilo y P3 representa un grupo protector amina bencílico, para dar un compuesto de formula (4), o una sal del mismo, seguido de la eliminacion de cualquier grupo protector P1, P2 y P3 y, si se desea, formando una sal de adicion de ácido aceptable para uso farmacéutico. Reivindicacion 5: Una composicion farmacéutica, caracterizada porque comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 2 y un vehículo aceptable para uso farmacéutico. Reivindicacion 6: Una composicion farmacéutica de acuerdo con al reivindicacion 5, caracterizada porque además comprende un esteroide. Reivindicacion 7: Una composicion farmacéutica de acuerdo con la reivindicacion 6, caracterizada porque el esteroide es beclometasona, triamcinolona, funisolida, mometasona, budesonida o fluticasona. Reivindicacion 17: Un compuesto de acuerdo con cualquiera de las reivindicaciones 1 o 2, para uso en terapia. Reivindicacion 18: Uso de un compuesto de acuerdo con la reivindicacion 1 o la reivindicacion 2, caracterizada porque es para la preparacion de un medicamento para el tratamiento de broncoconstriccion asociada con una enfermedad obstructiva reversible de las vías respiratorias.
ARP080103726A 2007-08-28 2008-08-27 Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo AR072943A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96643807P 2007-08-28 2007-08-28

Publications (1)

Publication Number Publication Date
AR072943A1 true AR072943A1 (es) 2010-10-06

Family

ID=40291128

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080103726A AR072943A1 (es) 2007-08-28 2008-08-27 Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo

Country Status (12)

Country Link
US (4) US8501994B2 (es)
EP (1) EP2195285B1 (es)
JP (1) JP5468543B2 (es)
KR (1) KR101398775B1 (es)
AR (1) AR072943A1 (es)
AU (1) AU2008296458B2 (es)
CA (1) CA2696943C (es)
ES (1) ES2684125T3 (es)
MX (1) MX2010001978A (es)
NZ (1) NZ583462A (es)
TW (1) TWI505826B (es)
WO (1) WO2009032764A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US8501994B2 (en) * 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
CN111944855B (zh) * 2020-09-03 2022-08-30 扬州中宝药业股份有限公司 一种合成(r)-1-(4-(苄氧基)-3-硝基苯基)-2-溴乙醇的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4880523A (es) * 1972-02-05 1973-10-29
DE2305092A1 (de) 1972-02-05 1973-08-16 Yamanouchi Pharma Co Ltd Alpha-aminomethylbenzylalkoholderivate
GB1415256A (en) 1972-02-05 1975-11-26 Yamanouchi Pharma Co Ltd Alpha-aminomethylbenzyl alcohol derivatives
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
JPS599542B2 (ja) * 1980-06-11 1984-03-03 山之内製薬株式会社 新規な３−アシルアミノ−４−ヒドロキシ−α−（アラルキルアミノメチル）ベンジルアルコ−ルの製法
ES2005492A6 (es) 1987-12-23 1989-03-01 Lasa Lab Procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2((2- (4-metoxifenil)-1metiletil)amino)etil)fenil)foramida (i).
ES2031407A6 (es) 1988-10-05 1992-12-01 Lasa Lab Mejoras introducidas en el objeto de la patente principal n{ 8703715 por: procedimiento de obtencion de n-(2-hidroxi-5-(1-hidroxi-2-((2-(4-metoxifenil)-1-metiletil)amino)etil)fenil)formamida".
AU715233B2 (en) 1996-01-10 2000-01-20 Asahi Kasei Kogyo Kabushiki Kaisha Novel tricyclic compounds and drug compositions containing the same
ES2178015T3 (es) 1996-11-11 2002-12-16 Sepracor Inc Procedimiento de preparacion de isomeros de formoterol opticamente puros.
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
US6472563B1 (en) 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
US7718822B2 (en) * 2007-08-28 2010-05-18 Sepracor Inc. Carbamate Stereoisomer
US8501994B2 (en) * 2007-08-28 2013-08-06 Sunovion Pharmaceuticals Inc. Acetamide stereoisomer

Also Published As

Publication number Publication date
AU2008296458B2 (en) 2014-01-16
MX2010001978A (es) 2010-05-27
US20090060922A1 (en) 2009-03-05
KR101398775B1 (ko) 2014-05-27
EP2195285B1 (en) 2018-08-01
US20130296607A1 (en) 2013-11-07
US20140135300A1 (en) 2014-05-15
NZ583462A (en) 2012-03-30
WO2009032764A1 (en) 2009-03-12
EP2195285A1 (en) 2010-06-16
US9040588B2 (en) 2015-05-26
US9499476B2 (en) 2016-11-22
CA2696943A1 (en) 2009-03-12
KR20100047333A (ko) 2010-05-07
ES2684125T3 (es) 2018-10-01
AU2008296458A1 (en) 2009-03-12
JP5468543B2 (ja) 2014-04-09
CA2696943C (en) 2015-05-26
US8501994B2 (en) 2013-08-06
TWI505826B (zh) 2015-11-01
US20150225334A1 (en) 2015-08-13
US8664441B2 (en) 2014-03-04
JP2010538010A (ja) 2010-12-09
TW200913984A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
AR072943A1 (es) Estereo isomero de metil-(2-hidroxi-5-(((2-(4-hidroxifenil)-1-metiletil)amino)etil)fenil)-acetamida, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo
CA2666612A1 (en) Methods, compositions, and formulations for the treatment of thyroid eye disease
RU2013104401A (ru) Фармацевтический препарат, содержащий ингибитор фосфодиэстеразы
JP2018199684A5 (es)
BR112016023679A2 (pt) derivados de amida e sais farmaceuticamente aceitáveis dos mesmos, método de preparação dos mesmos e aplicação medicinal dos mesmos
CA2905457A1 (en) Treatment of cataplexy
NZ606548A (en) Dry powder formulation comprising a phosphodiesterase inhibitor
BR112013027028A2 (pt) preparo de gadobutrol de alta pureza
KR101793777B1 (ko) 만성 폐쇄성 폐 질환의 급성 악화의 치료에서의 피라졸 유도체의 용도
BR112014004963A2 (pt) sal de colina do composto anti-inflamatório ciclobutanodiona substituído
RU2010108640A (ru) Новая комбинация терапевтических агентов
BR112014009927A2 (pt) "derivado de azol, composição farmacêutica que o compreende e uso do mesmo"
JP2016516074A5 (es)
IN2014DN05869A (es)
JP2017513824A5 (es)
RU2018103940A (ru) Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза
ES2568497T3 (es) Uso de una composición que comprende formoterol y dipropionato de beclometasona para el tratamiento de una exacerbación de asma
BRPI0417268B8 (pt) compostos benzimidazóis que contêm morfolinila, seu uso como inibidores da replicação de vírus sinciciais respiratórios, composição que os compreende e processo para preparar os referidos compostos
CL2013003630A1 (es) Formulacion farmaceutica liquida que comprende nitisinona y un tampon de acido citrico que tien un ph en el rango de 2,5 a 3,5, de preferencia 3,0; y su uso para el tratamiento de tirosemia, enfermedad de parkinson, depresion, entre otros.
RU2008108175A (ru) Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы
BR112013018598A2 (pt) composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca
AR071045A1 (es) Estereo isomero de metil-( 2-hidroxi-5- (((2-(4-hidroxifenil)-1-metiletil) amino)etil)fenil)- carbamato, mezcla de sus isomeros, proceso de preparacion del mismo, una composicion farmaceutica que contiene a dicho carbamato y uso del mismo
AR043510A1 (es) Derivados de quinolinona, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden
JP2010538010A5 (es)
US10835514B2 (en) Dry powder inhaler compositions of 7-azoniabicyclo[2.2.1]heptane derivatives

Legal Events

Date Code Title Description
FB Suspension of granting procedure